Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
Loading
Gross Profit Growth Under PressureDecelerating
Percentile Rank10
Year-over-Year Change
Year-over-year gross profit growth rate
Percentile
P10
Near historical low
vs 5Y Ago
-0.6x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -21.15% |
| Q3 2025 | 66.76% |
| Q2 2025 | 20.57% |
| Q1 2025 | 6.69% |
| Q4 2024 | 18.15% |
| Q3 2024 | -29.80% |
| Q2 2024 | 38.00% |
| Q1 2024 | 21.05% |
| Q4 2023 | -46.89% |
| Q3 2023 | 185.46% |
| Q2 2023 | -11.74% |
| Q1 2023 | -6.82% |
| Q4 2022 | 27.14% |
| Q3 2022 | 21.29% |
| Q2 2022 | 3.59% |
| Q1 2022 | -19.58% |
| Q4 2021 | 42.53% |
| Q3 2021 | -14.76% |
| Q2 2021 | 24.09% |
| Q1 2021 | 4.25% |
| Q4 2020 | 35.06% |
| Q3 2020 | 23.83% |
| Q2 2020 | -2.48% |
| Q1 2020 | 44.82% |
| Q4 2019 | -8.24% |
| Q3 2019 | 60.56% |
| Q2 2019 | 34.86% |
| Q1 2019 | 54.62% |
| Q4 2018 | 902.48% |
| Q3 2018 | -93.54% |
| Q2 2018 | 36.57% |
| Q1 2018 | -42.26% |
| Q4 2017 | 121.83% |
| Q3 2017 | 7.31% |
| Q2 2017 | -15.97% |
| Q1 2017 | 8.63% |
| Q4 2016 | 27.86% |
| Q3 2016 | 56.75% |
| Q2 2016 | 18.57% |
| Q1 2016 | -2.73% |